Presentation is loading. Please wait.

Presentation is loading. Please wait.

DKTK MASTER is an example of whole-exome and transcriptome sequencing-based precision oncology programme. DKTK MASTER is an example of whole-exome and.

Published bySusan Baker Modified over 5 years ago

Similar presentations

Presentation on theme: "DKTK MASTER is an example of whole-exome and transcriptome sequencing-based precision oncology programme. DKTK MASTER is an example of whole-exome and."— Presentation transcript:

1 DKTK MASTER is an example of whole-exome and transcriptome sequencing-based precision oncology programme. DKTK MASTER is an example of whole-exome and transcriptome sequencing-based precision oncology programme. Following patient consent and study enrolment, biopsies are taken and processed in a certified laboratory using standardised protocols and storage methods. Pathological diagnosis and tumour cell content are validated by an independent pathologist. After DNA and RNA isolation and library preparation, NGS on an Illumina HiSeq 2500 platform is performed. Bioinformatical analysis is followed by data curation and validation of putative molecular targets. Following discussion in a molecular tumour board meeting, further enrolment in clinical trials and other personalised treatment strategies are recommended. CNV, copy number variant; FISH, fluorescence in situ hybridisation; NGS, next-generation sequencing; NCT IIT, National Center for Tumour Diseases investigator initiated trial; qRT-PCR, quantitative real-time polymerase chain reaction; SNV, single nucleotide variant. Peter Horak et al. ESMO Open 2016;1:e000094 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "DKTK MASTER is an example of whole-exome and transcriptome sequencing-based precision oncology programme. DKTK MASTER is an example of whole-exome and."

Similar presentations

Ulrik Lassen MD, PH.D Phase 1 Unit

Ulrik Lassen MD, PH.D Phase 1 Unit
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.

INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Implementation of a Reliable Next-Generation Sequencing Strategy for Molecular Diagnosis of Dystrophinopathies  Melissa Alame, Delphine Lacourt, Reda.

Implementation of a Reliable Next-Generation Sequencing Strategy for Molecular Diagnosis of Dystrophinopathies  Melissa Alame, Delphine Lacourt, Reda.
Proposal of a simplified treatment algorithm in patients with cancer and liver cirrhosis. 1 Both tumour- and liver-related prognosis should be taken into.

Proposal of a simplified treatment algorithm in patients with cancer and liver cirrhosis. 1 Both tumour- and liver-related prognosis should be taken into.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes

Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes
(A) Timeline of the patient’s clinical events and interventions.

(A) Timeline of the patient’s clinical events and interventions.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,
Next-Generation Sequencing: Methodology and Application

Next-Generation Sequencing: Methodology and Application
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.
Low Copy Number DNA Template Can Render Polymerase Chain Reaction Error Prone in a Sequence-Dependent Manner  Mansour Akbari, Marianne Doré Hansen, Jostein.

Low Copy Number DNA Template Can Render Polymerase Chain Reaction Error Prone in a Sequence-Dependent Manner  Mansour Akbari, Marianne Doré Hansen, Jostein.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Similar presentations

Ads by Google